Gamida Cell INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$461Kgeneral payments (2019-2025)
$0.00research payments (2019-2025)
151clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Ivan Borrello | Tampa, FL | Medical Oncology | $182,619.00 |
| Stephanie Tsai | Maywood, IL | Hematology (Internal Medicine) | $33,613.63 |
| Filippo Milano | Seattle, WA | Hematology & Oncology | $21,886.49 |
| Mitchell Horwitz | Durham, NC | Infectious Disease | $16,240.39 |
| Akshay Sharma | Memphis, TN | Pediatric Hematology-Oncology | $14,480.00 |
| Julio Alvarenga Thiebaud | Dallas, TX | Hematology & Oncology | $12,733.43 |
| Zachary Crees | Saint Louis, MO | Medical Oncology | $11,866.06 |
| Jonathan Gutman | Aurora, CO | Medical Oncology | $11,670.00 |
| Mhd Monzr Al Malki | Duarte, CA | Hematology (Internal Medicine) | $11,560.01 |
| Paibel Aguayo-Hiraldo | Los Angeles, CA | Pediatric Hematology-Oncology | $10,733.31 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.